HNP-2

General Information


DRACP ID  DRACP00023

Peptide Name   HNP-2

Sequence  CYCRIPACIAGERRYGTCIYQGRLWAFCC

Sequence Length  29

UniProt ID  P59666  P59665  Q6EZE9  G3QPD5 

PubChem CID  Not available

Origin  Human alpha-defensins

Type  Native peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
RCCs (A-498, Caki-2, 786-0, 769-P, ACHN, LE 9211-RCC, TW33, N43) Renal Cell Carcinoma Carcinoma At higher concentrations than 25 μg/ml, HNPs-1, -2, and -3 exerted cytotoxic effects on all tested RCC lines in an in vitro serum-free culture system (at lower concentrations they stimulated cell grow WST-1 assay  40 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00023

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys1<--->Cys29; Cys9<--->Cys18; Cys8<--->Cys28

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C147H223N43O37S6

Absent amino acids  DHKMNSV

Common amino acids  C

Mass  387665

Pl  8.37

Basic residues  4

Acidic residues  1

Hydrophobic residues  9

Net charge  3

Boman Index  -3410

Hydrophobicity  24.83

Aliphatic Index  64.14

Half Life 
  Mammalian: 4.4 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  10345

Absorbance 280nm  369.46

Polar residues  13

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 11943716

Title  Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation

Doi 10.1016/s0002-9440(10)62558-8

Year  2002

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




CancerPPD ID  4431

DRACP is developed by Dr.Zheng's team.